226 related articles for article (PubMed ID: 36933456)
1. [
Vats K; Chakraborty A; Rakshit S; Damle A; Sarma HD; Satpati D
Nucl Med Biol; 2023; 118-119():108331. PubMed ID: 36933456
[TBL] [Abstract][Full Text] [Related]
2. Development and Preclinical Evaluation of
Makris G; Bandari RP; Kuchuk M; Jurisson SS; Smith CJ; Hennkens HM
Mol Imaging Biol; 2021 Feb; 23(1):52-61. PubMed ID: 32886303
[TBL] [Abstract][Full Text] [Related]
3. [
Kanellopoulos P; Lymperis E; Kaloudi A; de Jong M; Krenning EP; Nock BA; Maina T
Molecules; 2020 Jul; 25(15):. PubMed ID: 32731473
[No Abstract] [Full Text] [Related]
4. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma.
Liu Z; Huang J; Dong C; Cui L; Jin X; Jia B; Zhu Z; Li F; Wang F
Mol Pharm; 2012 May; 9(5):1409-17. PubMed ID: 22452411
[TBL] [Abstract][Full Text] [Related]
5. (99m)technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model.
Ananias HJ; Yu Z; Dierckx RA; van der Wiele C; Helfrich W; Wang F; Yan Y; Chen X; de Jong IJ; Elsinga PH
Mol Pharm; 2011 Aug; 8(4):1165-73. PubMed ID: 21699202
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
7. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
[TBL] [Abstract][Full Text] [Related]
8. (99m)Tc-labeled SWL specific peptide for targeting EphA2 receptor.
Liu Y; Lan X; Wu T; Lang J; Jin X; Sun X; Wen Q; An R
Nucl Med Biol; 2014 Jul; 41(6):450-6. PubMed ID: 24768147
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a New
Farahani AM; Maleki F; Sadeghzadeh N; Abediankenari S; Abedi SM; Erfani M
Anticancer Agents Med Chem; 2020; 20(14):1695-1703. PubMed ID: 32560611
[TBL] [Abstract][Full Text] [Related]
10. Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man study.
Ananias HJ; Yu Z; Hoving HD; Rosati S; Dierckx RA; Wang F; Yan Y; Chen X; Pruim J; Lub-de Hooge MN; Helfrich W; Elsinga PH; de Jong IJ
Nucl Med Biol; 2013 Oct; 40(7):933-8. PubMed ID: 23891351
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Stabilized SB3, an Attractive GRPR Antagonist, for Pre- and Intra-Operative Imaging for Prostate Cancer.
Bakker IL; van Tiel ST; Haeck J; Doeswijk GN; de Blois E; Segbers M; Maina T; Nock BA; de Jong M; Dalm SU
Mol Imaging Biol; 2018 Dec; 20(6):973-983. PubMed ID: 29556947
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of (99m)Tc-HYNIC-TMTP1 as a tumor-homing imaging agent targeting metastasis with SPECT.
Li F; Cheng T; Dong Q; Wei R; Zhang Z; Luo D; Ma X; Wang S; Gao Q; Ma D; Zhu X; Xi L
Nucl Med Biol; 2015 Mar; 42(3):256-62. PubMed ID: 25516099
[TBL] [Abstract][Full Text] [Related]
13. [
Kaihani S; Sadeghzadeh N; Abediankenari S; Abedi SM
Ann Nucl Med; 2022 Nov; 36(11):976-985. PubMed ID: 36097232
[TBL] [Abstract][Full Text] [Related]
14. Substitution of l-Tryptophan by
Günther T; Deiser S; Felber V; Beck R; Wester HJ
J Nucl Med; 2022 Sep; 63(9):1364-1370. PubMed ID: 35027371
[TBL] [Abstract][Full Text] [Related]
15. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer.
Yu Z; Carlucci G; Ananias HJ; Dierckx RA; Liu S; Helfrich W; Wang F; de Jong IJ; Elsinga PH
Amino Acids; 2013 Feb; 44(2):543-53. PubMed ID: 22833158
[TBL] [Abstract][Full Text] [Related]
17. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
18. Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting.
Damiana TST; Paraïso P; de Ridder C; Stuurman D; Seimbille Y; Dalm SU
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3851-3861. PubMed ID: 37584725
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
